Carol Suh
Founder of Neumora
San Francisco Bay Area
Overview
Work Experience
Partner
2021 - Current
Board Member: Orbital Therapeutics, Human Immunology Biosciences (acquired by Biogen in 2024 for up to $1.8B) Board Observer: Kisbee Therapeutics (2021-Present), Remix Therapeutics (2021-Present), Resonance Medicine (2021-2023), Sesh Therapy (2021-2023), Locana Bio (2020-2024), CERo Therapeutics (2020-2022), Metacrine (2019-2020),
Principal
2019 - 2021
Senior Associate
2018 - 2019
Consultant/Intern
2018 - 2018
ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.
Co-Founder and Chief Strategy Officer
2025
Co-Founder and Chief Operating Officer
2023 - 2025
Co-Founder and SVP, Strategy
2022 - 2023
Co-founder and VP, Business Development
2019 - 2021
Co-founder, Board Member
2022
Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease in ways that were not previously possible. The company is leveraging its first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of immunomodulation for autoimmune disease and oncology, next-generation vaccines, and protein therapeutics.
Orbital Therapeutics is a biotechnology company that develops RNA-based medicines to treat disease in humans.
Raised $270,000,000.00 from Andreessen Horowitz, Invus, Redmile Group, EXOR N.V., Rellim Capital Management, ARCH Venture Partners, Newpath Management, Abu Dhabi Growth Fund, Agent Capital and iGlobe Partners.
Board Member of CODA (Complex Disorders Alliance)
2021
CODA is an innovative, patient-founded, patient-focused, nonprofit organization with a mission to accelerate data-driven research for complex disorders. Formerly known as Metrodora Foundation.
Board Member
2021 - 2024
Human Immunology Biosciences, Inc. (HI-Bio™), was incubated by ARCH Venture Partners and Monograph Capital to develop precision therapies for immune-mediated diseases and to bring clinical immunology into its next chapter. Acquired by Biogen for up to $1.8B. https://investors.biogen.com/news-releases/news-release-details/biogen-bolsters-late-stage-pipeline-expands-immunology-portfolio
Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases.
Raised $215,000,000.00 from Alpha Wave Global, Jeito Capital, ARCH Venture Partners, Arkin Holdings and Viking Global Investors.
Associate Director of Corporate Development
2019 - 2019
ARCH Venture Partners company build. Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients.
Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.
Raised $251,400,000.00 from Nextech Invest, Piper Heartland Healthcare Capital, ARCH Venture Partners, RA Capital Management, Wellington Management, Surveyor Capital, Fidelity, Logos Capital, City Hill Ventures and Alexandria Venture Investments.
Business Development and Corporate Strategy Associate; Launch Fellow
2016 - 2017
Business Development and Corporate Strategy Associate (Jun 2017-Sept 2017) Launch Fellow (May 2016-Aug 2016): Helped prepare Magenta Therapeutics for launch and $48.5M Series A, working with Third Rock Ventures and Atlas Venture.
Senior Associate Consultant
2015 - 2016
Senior Associate Consultant (2016) Associate Consultant (2015)
Trinity provides strategic and tactical insights to address the complex business questions that confront pharmaceutical, biotech.
R&D Strategy; Innovation Fellow
2014 - 2014
The Regenerative Medicine Discovery Performance Unit built a portfolio of innovative stem cell and regenerative medicines through in-house R&D, strategic alliances, and in-licensing opportunities.